190 related articles for article (PubMed ID: 21333004)
1. Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity.
Naruo Y; Nagashima T; Ushikoshi-Nakayama R; Saeki Y; Nakakuki T; Naka T; Tanaka H; Tsai SF; Okada-Hatakeyama M
BMC Syst Biol; 2011 Feb; 5():29. PubMed ID: 21333004
[TBL] [Abstract][Full Text] [Related]
2. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
[TBL] [Abstract][Full Text] [Related]
3. Mutation of epidermal growth factor receptor is associated with MIG6 expression.
Nagashima T; Ushikoshi-Nakayama R; Suenaga A; Ide K; Yumoto N; Naruo Y; Takahashi K; Saeki Y; Taiji M; Tanaka H; Tsai SF; Hatakeyama M
FEBS J; 2009 Sep; 276(18):5239-51. PubMed ID: 19674104
[TBL] [Abstract][Full Text] [Related]
4. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Chang X; Izumchenko E; Solis LM; Kim MS; Chatterjee A; Ling S; Monitto CL; Harari PM; Hidalgo M; Goodman SN; Wistuba II; Bedi A; Sidransky D
PLoS One; 2013; 8(7):e68966. PubMed ID: 23935914
[TBL] [Abstract][Full Text] [Related]
5. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
Siu A; Virtanen C; Jongstra J
Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779
[TBL] [Abstract][Full Text] [Related]
6. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
Endo H; Okami J; Okuyama H; Nishizawa Y; Imamura F; Inoue M
Oncogene; 2017 May; 36(20):2824-2834. PubMed ID: 27893711
[TBL] [Abstract][Full Text] [Related]
7. MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription.
Zhang H; Liu W; Wang Z; Meng L; Wang Y; Yan H; Li L
Tumori; 2018 Jun; 104(3):221-231. PubMed ID: 29714661
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
[TBL] [Abstract][Full Text] [Related]
9. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
[TBL] [Abstract][Full Text] [Related]
10. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.
Furcht CM; Muñoz Rojas AR; Nihalani D; Lazzara MJ
Oncogene; 2013 May; 32(18):2346-55, 2355.e1-10. PubMed ID: 22777356
[TBL] [Abstract][Full Text] [Related]
11. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
[TBL] [Abstract][Full Text] [Related]
12. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells.
Walsh AM; Lazzara MJ
J Cell Sci; 2013 Oct; 126(Pt 19):4339-48. PubMed ID: 23868981
[TBL] [Abstract][Full Text] [Related]
13. DNAJB1 negatively regulates MIG6 to promote epidermal growth factor receptor signaling.
Park SY; Choi HK; Seo JS; Yoo JY; Jeong JW; Choi Y; Choi KC; Yoon HG
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2722-30. PubMed ID: 26239118
[TBL] [Abstract][Full Text] [Related]
14. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D
Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724
[TBL] [Abstract][Full Text] [Related]
15. Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.
Kim Y; Li Z; Apetri M; Luo B; Settleman JE; Anderson KS
Biochemistry; 2012 Jun; 51(25):5212-22. PubMed ID: 22657099
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
17. Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.
Misumi K; Sun J; Kinomura A; Miyata Y; Okada M; Tashiro S
Cancer Sci; 2016 Apr; 107(4):444-51. PubMed ID: 26825989
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
19. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
20. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]